HVEM/TNFRSF14 Protein, Human (Biotinylated, HEK293, Fc-Avi)

The HVEM/TNFRSF14 protein acts as a receptor for four ligands, including TNFSF14/LIGHT, LTA/lymphotoxin-α, BTLA, and CD160, forming a complex stimulatory and inhibitory signaling network. Utilizes the TRAF2-TRAF3 E3 ligase pathway to promote the survival and differentiation of immune cells. HVEM/TNFRSF14 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived HVEM/TNFRSF14 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

HVEM/TNFRSF14, a receptor for four distinct ligands, intricately orchestrates a complex network of stimulatory and inhibitory signaling pathways. Ligands, including TNFSF14/LIGHT, homotrimeric LTA/lymphotoxin-alpha, and immunoglobulin superfamily members BTLA and CD160, collectively define this intricate signaling network. Operating through the TRAF2-TRAF3 E3 ligase pathway, HVEM/TNFRSF14 signals to promote immune cell survival and differentiation, playing a pivotal role in bidirectional cell-cell contact signaling between antigen-presenting cells and lymphocytes. Upon TNFSF14/LIGHT ligation, HVEM/TNFRSF14 delivers costimulatory signals to T cells, fostering cell proliferation and effector functions. Interactions with CD160 on NK cells enhance IFNG production and anti-tumor immune responses. In bacterial infections, HVEM/TNFRSF14 acts as a signaling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and pro-inflammatory cytokines. Furthermore, HVEM/TNFRSF14, through binding CD160 on activated CD4+ T cells, down-regulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune responses. HVEM/TNFRSF14 exhibits both cis and trans interactions with BTLA, playing diverse roles in immune regulation and survival signaling during adaptive immune responses. Additionally, as a receptor for Herpes simplex virus 1/HHV-1, HVEM/TNFRSF14 is implicated in microbial infection.

Immobilized Human LIGHT mFc at 2 μg/mL (100 μL/well) can bind Biotinylated Human HVEM Fc-Avi with a linear range of 0.6-39 ng/mL.

Human

HEK293

C-Avi;C-hFc

Q92956-1 (L39-V202)

8764  [NCBI]

Approximately 55-66 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized a 0.22 μm filtered solution of Tris with Glycine, Arginine and NaCl, pH 7.5. Normally trehalose is added as protectant before lyophilization.
Note: For SPR assay, please replace the buffer. Primary amine components (e.g., Tris, imidazole) can affect protein-coupled chips.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.